Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Investigate the Properties of Topical Twice Daily Doses of 2.5% and 5% Cis-urocanic Acid in Comparison to Active Comparator 0.1% Protopic® for up to 28 Days in Patients With Moderate or Severe Atopic Dermatitis

NCT01320579 is registered in ClinicalTrials.gov with BioCis Pharma Ltd as lead sponsor.

NCT NCT01320579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01320579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Investigate the Properties of Topical Twice Daily Doses of 2.5% and 5% Cis-urocanic Acid in Comparison to Active Comparator 0.1% Protopic® for up to 28 Days in Patients With Moderate or Severe Atopic Dermatitis
Lead sponsor
BioCis Pharma Ltd
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
June 30, 2012
Enrollment
159 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis